All In Biotech

Drug Trial Radar · NCT07181382

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Followed by a Long-Term Extension Evaluating Safety and Efficacy

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingPhase 3. Randomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

480

Planned (sponsor's estimate)

Start

Feb 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
GB002, Inc.Industry
Sponsor type
Industry
Collaborators
Chiesi Farmaceutici S.p.A.
First posted
Sep 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study is designed as a 24-week randomized, double-blind, placebo-controlled period (PCP) followed by a 144-week long-term extension (LTE) period. The primary objective of the PCP is to evaluate the effect of seralutinib on improving exercise capacity in subjects with World Health Organization (WHO) Group 3 pulmonary hypertension associated with interstitial lung disease. The primary objective of the LTE is to evaluate the long-term safety and tolerability of seralutinib.

Conditions

  • Pulmonary Hypertension Associated With Interstitial Lung Disease

Interventions

  • PlaceboDrug

    Matching capsule containing placebo

  • SeralutinibDrug

    Capsule containing seralutinib

  • Generic Dry Powder InhalerDevice

    Generic dry powder inhaler for seralutinib or placebo delivery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in distance achieved on the six-minute walk test (6MWT), from baseline to PCP Week 24Time frame: Baseline to PCP Week 24
  2. Incidence of treatment-emergent adverse eventsTime frame: From first dose of LTE study treatment through LTE Week 148

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Valley Advanced Lung Diseases Institute

    Fresno, California

  • University of New Mexico Health Sciences Center

    Albuquerque, New Mexico

  • Pulmonary Associates of Richmond, Inc.

    Richmond, Virginia

  • Hillel Yaffe Medical Center

    Hadera, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.